Building an anticancer strategy takes time and the history of anti-HER drugs development reflects the challenge that each new molecular marker faces until the approval of a targeted therapy for ...
A phase II/III randomized study in advanced non-small cell lung cancer (NSCLC) with first line combination versus sequential gemcitabine and docetaxel: Interim study results No significant financial ...
Effect of IKKϵ knock-down on prostate cancer xenograft growth. Background: Activating EGFR mutations have become a backbone in the therapy alogrithm for NSCLC as mutations predict significantly better ...
Young lung cancer patients have a higher incidence of targetable biomarkers, necessitating comprehensive testing for ALK fusions and EGFR mutations. Repeat biomarker testing is essential when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results